Efficient local delivery of FK506 using blocking patches in psoriasis

J Colloid Interface Sci. 2023 Jan 15;630(Pt A):676-687. doi: 10.1016/j.jcis.2022.09.146. Epub 2022 Oct 5.

Abstract

FK506 is a local drug that is commonly used in the treatment of psoriasis. Its clinical application, however, is limited by its transdermal drug delivery rate, the time-consuming, and the greasy therapy. In this study, which was inspired by local block injection used in the clinical treatment for keloid, a hyaluronic acid (HA) based system to transport FK506 into the skin to treat psoriasis, named blocking patch (BP) was developed. BP has a complete appearance, sufficient puncture strength, and is virtually non-irritating in vivo. By confocal fluorescence microscopy, BP loaded with FK506 (FK506-BP) showed satisfactory transdermal release ability in vivo. Further animal studies revealed that FK506-BP showed a good anti-inflammatory ability in the imiquimod (IMQ)-induced mouse psoriasis-like dermatitis and inhibited the activation of associated immune cells. This study indicates that BP as a novel delivery system, realizes an efficient local delivery of FK506 in psoriasis and holds great potential in transdermal delivery.

Keywords: Anti-inflammation; Blocking patch; FK506; Microneedle; Psoriasis; Skin; Transdermal drug delivery.

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Imiquimod / adverse effects
  • Mice
  • Mice, Inbred BALB C
  • Psoriasis* / chemically induced
  • Psoriasis* / drug therapy
  • Skin
  • Tacrolimus* / adverse effects

Substances

  • Tacrolimus
  • Imiquimod